Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 961

1.

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.

Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6.

2.

Biopsy-diagnosed renal granuloma after intravesical bacillus Calmette-Guérin therapy for bladder carcinoma: a case series and review of the literature.

Narita K, Akita H, Kikuchi E, Nakahara T, Okuda S, Nakatsuka S, Oya M, Jinzaki M.

BJR Case Rep. 2019 Nov 15;5(4). pii: bjrcr.20190012. doi: 10.1259/bjrcr.20190012. eCollection 2019 Dec.

3.

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report.

Hongo H, Kosaka T, Aimono E, Nishihara H, Oya M.

Diagn Pathol. 2020 Jan 13;15(1):5. doi: 10.1186/s13000-019-0916-z.

4.

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.

Uemura M, Tomita Y, Miyake H, Hatakeyama S, Kanayama HO, Numakura K, Takagi T, Kato T, Eto M, Obara W, Uemura H, Choueiri TK, Motzer RJ, Fujii Y, Kamei Y, Umeyama Y, di Pietro A, Oya M.

Cancer Sci. 2019 Dec 28. doi: 10.1111/cas.14294. [Epub ahead of print]

5.

Splenic cord capillary hemangioma with non-islet cell tumor hypoglycemia: a case report.

Daimon T, Kosaka T, Horinaga M, Saito J, Ueyama Y, Matsuzaki S, Oya M.

Diagn Pathol. 2019 Dec 16;14(1):135. doi: 10.1186/s13000-019-0915-0.

6.

Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.

Takeda T, Tin AL, Corradi RB, Alvim R, Hashimoto T, Ito Y, Nguyen DP, Mamoor M, Robertson NL, Vargas HA, Benfante NE, Sjoberg DD, Eastham JA, Scardino PT, Fine SW, Oya M, Touijer KA.

Int J Urol. 2019 Dec 13. doi: 10.1111/iju.14161. [Epub ahead of print]

PMID:
31833113
7.

Factors affecting renal function preservation among patients not achieving trifecta after laparoscopic partial nephrectomy for clinical T1a renal masses.

Takeda T, Komatsuda A, Yanai Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Mizuno R, Shinojima T, Asanuma H, Oya M.

Asian J Endosc Surg. 2019 Dec 9. doi: 10.1111/ases.12776. [Epub ahead of print]

PMID:
31814326
8.

Usefulness of contrast-enhanced ultrasonography for diagnosis of renal cell carcinoma in dialysis patients: Comparison with computed tomography.

Hashimoto M, Ohkuma K, Akita H, Yamada Y, Nakatsuka S, Mizuno R, Oya M, Jinzaki M.

Medicine (Baltimore). 2019 Nov;98(47):e18053. doi: 10.1097/MD.0000000000018053.

9.

Characteristics of subcutaneous tissues at the site of insertion of peripheral infusion in patients undergoing paclitaxel and carboplatin chemotherapy.

Murayama R, Oya M, Abe-Doi M, Oe M, Komiyama C, Sanada H.

Drug Discov Ther. 2019;13(5):288-293. doi: 10.5582/ddt.2019.01064.

10.

Endoscopic submucosal dissection with a grasping-type scissors for early colorectal epithelial neoplasms: a large single-center experience.

Akahoshi K, Shiratsuchi Y, Oya M, Koga H, Kubokawa M, Nakama N, Akahoshi K, Ihara E.

VideoGIE. 2019 Jul 4;4(10):486-492. doi: 10.1016/j.vgie.2019.05.003. eCollection 2019 Oct.

11.
12.

A case of primary breast angiosarcoma with multiple discontinuous small lesions.

Sasahara A, Tanabe M, Hayashi K, Konishi T, Oya M, Sakiyama K, Morizono A, Harada M, Otsuji K, Ishibashi Y, Sato A, Kikuchi Y, Niwa T, Hinata M, Nishioka K, Seto Y.

Surg Case Rep. 2019 Oct 25;5(1):157. doi: 10.1186/s40792-019-0704-8.

13.

Utility of Hyperbaric Oxygen Therapy for Acute Acoustic Trauma: 20 years' Experience at the Japan Maritime Self-Defense Force Undersea Medical Center.

Oya M, Tadano Y, Takihata Y, Ikomi F, Tokunaga T.

Int Arch Otorhinolaryngol. 2019 Oct;23(4):e408-e414. doi: 10.1055/s-0039-1688433. Epub 2019 May 28.

14.

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.

Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, Sugiyama T, Oya M, Fujii Y, Obara W, Motzer RJ, Uemura H.

Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.

PMID:
31633185
15.

A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.

Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.

Pathol Int. 2019 Dec;69(12):715-720. doi: 10.1111/pin.12860. Epub 2019 Oct 20.

PMID:
31631483
16.

The efficacy of the TachoSil binding suturing technique in laparoscopic partial nephrectomy to prevent the development of pseudoaneurysm.

Shigeta K, Matsumoto K, Abe T, Komatsuda A, Takeda T, Mizuno R, Kikuchi E, Asanuma H, Arita Y, Akita H, Jinzaki M, Miyajima A, Oya M.

Asian J Surg. 2019 Oct 16. pii: S1015-9584(19)30793-6. doi: 10.1016/j.asjsur.2019.09.002. [Epub ahead of print]

17.

Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.

Matsumoto K, Niwa N, Hagiwara M, Kosaka T, Tanaka N, Takeda T, Morita S, Mizuno R, Shinojima T, Hara S, Asanuma H, Oya M.

World J Urol. 2019 Sep 26. doi: 10.1007/s00345-019-02970-w. [Epub ahead of print]

PMID:
31559475
18.

A comparison of laparoendoscopic single-site surgery versus conventional procedures for laparoscopic donor nephrectomy: a Japanese multi-institutional retrospective study.

Inoue T, Miura M, Yanishi M, Furukawa J, Sato F, Nitta M, Yoshimura K, Hagiuda J, Shinoda K, Kobayashi T, Miyajima A, Nakagawa K, Oya M, Ogawa O, Mimata H, Kanayama HO, Fujisawa M, Terachi T, Matsuda T, Habuchi T; LESS and RPS Research Group in Japanese Society of Endourology.

Surg Endosc. 2019 Sep 23. doi: 10.1007/s00464-019-07119-9. [Epub ahead of print]

PMID:
31549237
19.

[Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].

Oya M, Tajima Y, Kabu K.

Gan To Kagaku Ryoho. 2019 Sep;46(9):1397-1404. Review. Japanese.

PMID:
31530779
20.

Successful perinatal management of a dichorionic diamniotic twin pregnancy in an anaemic kidney transplant patient treated with Darbepoetin alfa: a case report.

Tamaki S, Shinoda K, Matsumoto T, Morita S, Asanuma H, Yoshida T, Oya M.

J Obstet Gynaecol. 2019 Sep 3:1-3. doi: 10.1080/01443615.2019.1636776. [Epub ahead of print] No abstract available.

PMID:
31478423
21.

Advances in targeted alpha therapy for prostate cancer.

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O; Targeted Alpha Therapy Prostate Working Group .

Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270.

22.

A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma.

Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mikami S, Mizuno R, Oya M.

Eur Urol Oncol. 2019 Aug 5. pii: S2588-9311(19)30102-6. doi: 10.1016/j.euo.2019.06.021. [Epub ahead of print]

PMID:
31395480
23.

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Shirotake S, Takamatsu K, Mizuno R, Kaneko GO, Nishimoto K, Oya M, Oyama M.

Anticancer Res. 2019 Aug;39(8):4371-4377. doi: 10.21873/anticanres.13606.

PMID:
31366532
24.

Editorial Comment.

Yazawa S, Oya M, Nakajima Y.

J Urol. 2019 Nov;202(5):1000. doi: 10.1097/01.JU.0000578560.21169.3f. Epub 2019 Oct 9. No abstract available.

PMID:
31339421
25.
26.

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.

Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N, Yoshimura K, Fukasawa S, Ecstein-Fraisse E, Sunaga Y, Oya M.

Jpn J Clin Oncol. 2019 Aug 1;49(8):766-771. doi: 10.1093/jjco/hyz051.

27.

Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching.

Shigeta K, Kikuchi E, Abe T, Hagiwara M, Ogihara K, Anno T, Umeda K, Baba Y, Sanjo T, Shojo K, Mizuno R, Oya M.

Ann Surg Oncol. 2019 Oct;26(11):3774-3781. doi: 10.1245/s10434-019-07623-1. Epub 2019 Jul 16.

PMID:
31313043
28.

Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy.

Watanabe K, Kosaka T, Aimono E, Hongo H, Mikami S, Nishihara H, Oya M.

Clin Genitourin Cancer. 2019 Oct;17(5):e897-e902. doi: 10.1016/j.clgc.2019.06.005. Epub 2019 Jun 13. No abstract available.

PMID:
31296452
29.

TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.

Niwa N, Tanaka N, Hongo H, Miyazaki Y, Takamatsu K, Mizuno R, Kikuchi E, Mikami S, Kosaka T, Oya M.

Lab Invest. 2019 Nov;99(11):1702-1713. doi: 10.1038/s41374-019-0285-y. Epub 2019 Jul 1.

PMID:
31263157
30.

Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.

Takeda T, Benfante NE, Assel M, Mulhall JP, Oya M, Touijer KA.

Int J Urol. 2019 Sep;26(9):934-935. doi: 10.1111/iju.14043. Epub 2019 Jun 25. No abstract available.

PMID:
31240770
32.

Accidental Hypothermia Treated by Hemodialysis in the Acute Phase: Three Case Reports and a Review of the Literature.

Murakami T, Yoshida T, Kurokochi A, Takamatsu K, Teranishi Y, Shigeta K, Tamaki S, Morita S, Mizuno R, Oya M.

Intern Med. 2019 Sep 15;58(18):2743-2748. doi: 10.2169/internalmedicine.1945-18. Epub 2019 Jun 7. Review.

33.

Preserved Kidney Volume, Body Mass Index, and Age Are Significant Preoperative Factors for Predicting Estimated Glomerular Filtration Rate in Living Kidney Donors at 1 Year After Donation.

Shinoda K, Morita S, Akita H, Washizuka F, Tamaki S, Takahashi R, Oguchi H, Sakurabayashi K, Mizutani T, Takahashi Y, Hyodo Y, Itabashi Y, Muramatsu M, Kawamura T, Asanuma H, Kikuchi E, Jinzaki M, Shiraga N, Nakagawa K, Oya M, Shishido S, Sakai K.

Transplant Proc. 2019 Jun;51(5):1306-1310. doi: 10.1016/j.transproceed.2019.01.142. Epub 2019 May 7.

PMID:
31076152
34.

Physical Parameters, Use of Specific Medical Treatments, Nursing Levels, and Activities of Daily Living Are Potential Indicators for Forgoing Maintenance Hemodialysis.

Yamaguchi N, Yoshida T, Oba M, Nakano R, Saito M, Hirokawa M, Shinmi T, Urasawa C, Oya M.

Keio J Med. 2019 May 9. doi: 10.2302/kjm.2019-0001-OA. [Epub ahead of print]

35.

Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.

Takamatsu K, Mizuno R, Tanaka N, Takeda T, Morita S, Matsumoto K, Kosaka T, Shinojima T, Kikuchi E, Asanuma H, Oyama M, Mikami S, Oya M.

Int J Clin Oncol. 2019 Sep;24(9):1069-1074. doi: 10.1007/s10147-019-01459-1. Epub 2019 May 7.

PMID:
31065836
36.

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.

Kaneko G, Shirotake S, Nishimoto K, Miyazaki Y, Ito K, Ito Y, Hagiwara M, Kanao K, Nakagawa K, Momma T, Asano T, Tanaka N, Mizuno R, Oya M, Oyama M.

Jpn J Clin Oncol. 2019 Aug 1;49(8):780-785. doi: 10.1093/jjco/hyz067.

PMID:
31063191
37.

Pneumocystis jirovecii Pneumonia in an Immunocompetent Japanese Man: A Case Report and Literature Review.

Ide H, Yamaji Y, Tobino K, Okahisa M, Murakami K, Goto Y, Sueyasu T, Nishizawa S, Yoshimine K, Munechika M, Oya M, Hiraki Y.

Case Rep Pulmonol. 2019 Mar 7;2019:3981681. doi: 10.1155/2019/3981681. eCollection 2019.

38.

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer.

Cancer Sci. 2019 Jun;110(6):1820-1828. doi: 10.1111/cas.14019. Epub 2019 May 13.

39.

The prognostic value of zonal origin and extraprostatic extension of prostate cancer for biochemical recurrence after radical prostatectomy.

Takamatsu K, Matsumoto K, Shojo K, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M.

Urol Oncol. 2019 Sep;37(9):575.e19-575.e25. doi: 10.1016/j.urolonc.2019.03.012. Epub 2019 Apr 6.

PMID:
30967332
40.

A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.

Yoshimatsu K, Ishibashi K, Koda K, Yokomizo H, Oda N, Oshiro M, Kato H, Oya M, Nakajima H, Ooki S, Maekawa H, Matsunami T, Tsubaki M, Yamada T, Kobayashi M, Tanakaya K, Yokoyama M, Ishida H.

Surg Today. 2019 Jun;49(6):498-506. doi: 10.1007/s00595-019-1771-y. Epub 2019 Apr 5.

PMID:
30953164
41.

Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review.

Takahashi R, Shinoda K, Ishida T, Hamamoto Y, Morita S, Akita H, Kitaoka S, Tamaki S, Asanuma H, Yoshida T, Jinzaki M, Kameyama K, Oya M.

BMC Nephrol. 2019 Apr 3;20(1):120. doi: 10.1186/s12882-019-1310-5.

42.

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H.

Jpn J Clin Oncol. 2019 Jun 1;49(6):506-514. doi: 10.1093/jjco/hyz026.

PMID:
30941424
43.

The origin of p40-negative and CDX2-positive primary squamous cell carcinoma of the stomach: case report.

Yamagata Y, Saito K, Ban S, Fujii A, Oya M.

World J Surg Oncol. 2019 Mar 19;17(1):53. doi: 10.1186/s12957-019-1594-8.

44.

Effect of Awareness and Habits of Oral Care on Life Satisfaction.

Hirano M, Imai H, Oya M.

Oral Health Prev Dent. 2019;17(2):131-138. doi: 10.3290/j.ohpd.a42204.

PMID:
30874253
45.

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.

Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M.

Int J Clin Oncol. 2019 May;24(5):554-556. doi: 10.1007/s10147-019-01395-0.

PMID:
30826960
46.

A case with mesenteric desmoid tumor after laparoscopic resection of stage I sigmoid colon cancer.

Takada M, Okuyama T, Yoshioka R, Noie T, Takeshita E, Sameshima S, Oya M.

Surg Case Rep. 2019 Feb 28;5(1):38. doi: 10.1186/s40792-019-0587-8.

47.

Prediction of extraprostatic extension by MRI tumor contact length: difference between anterior and posterior prostate cancer.

Matsumoto K, Akita H, Narita K, Hashiguchi A, Takamatsu K, Takeda T, Kosaka T, Mizuno R, Kikuchi E, Oya M, Jinzaki M.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):539-545. doi: 10.1038/s41391-019-0136-3. Epub 2019 Feb 27.

PMID:
30814680
48.

Relationship of NEFA concentrations to RBP4 and to RBP4/retinol in prepubertal children with and without obesity.

Ortega-Senovilla H, de Oya M, Garcés C.

J Clin Lipidol. 2019 Mar - Apr;13(2):301-307. doi: 10.1016/j.jacl.2019.01.006. Epub 2019 Jan 23.

PMID:
30773418
49.

[Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report].

Makino H, Kametaka H, Fukada T, Akiyama T, Saitou M, Tabe S, Okura R, Oya M, Seike K, Yoshitomi H, Miyazaki M.

Gan To Kagaku Ryoho. 2019 Jan;46(1):142-144. Japanese.

PMID:
30765668
50.

[Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].

Mizuno R, Oya M.

Gan To Kagaku Ryoho. 2019 Jan;46(1):50-53. Japanese. No abstract available.

PMID:
30765642

Supplemental Content

Support Center